These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12914137)

  • 1. [Priorities by the board of drug benefits--guidelines clarify. Clinical trials are not sufficient for decisions on subsidizing].
    Carlsson P
    Lakartidningen; 2003 Jul; 100(30-31):2428-9. PubMed ID: 12914137
    [No Abstract]   [Full Text] [Related]  

  • 2. [Drug costs should be based on health economic benefits. A new law on drug benefits requires studies of health economic effects].
    Berggren F
    Lakartidningen; 2003 Jul; 100(30-31):2446-8. PubMed ID: 12914141
    [No Abstract]   [Full Text] [Related]  

  • 3. [Guidelines of the Pharmaceutical Benefits Board for health economics evaluations. Cost-efficiency analysis from a national perspective].
    Lundin D; Carlsson P; Levin LA; Persson U
    Lakartidningen; 2006 Nov 22-28; 103(47):3716-8. PubMed ID: 17212321
    [No Abstract]   [Full Text] [Related]  

  • 4. [Difficult standpoints to be taken by the committee of costs and subsidies].
    Persson U; Anell A; Jendteg S
    Lakartidningen; 2002 Jul; 99(30-31):3128-9. PubMed ID: 12198933
    [No Abstract]   [Full Text] [Related]  

  • 5. [Health economic evaluation of recommended drug treatment].
    Jendteg S; Persson U; Anell A
    Lakartidningen; 2002 Jul; 99(30-31):3130-1. PubMed ID: 12198934
    [No Abstract]   [Full Text] [Related]  

  • 6. [Follow up studies as a condition for drug subsidizing].
    Kieler H; Ekbom A; Fored M; Montgomery SM; Wettermark B
    Lakartidningen; 2009 May 13-19; 106(20):1406-7. PubMed ID: 19585842
    [No Abstract]   [Full Text] [Related]  

  • 7. Priority setting in practice: what is the best way to compare costs and benefits?
    Wilson EC; Peacock SJ; Ruta D
    Health Econ; 2009 Apr; 18(4):467-78. PubMed ID: 18561215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Increasing drug costs. The society's drug expenditures are strongly increasing. If this trend continues we have to make other priorities].
    Andreasen J
    Ugeskr Laeger; 2003 Jul; 165(29):2873-6. PubMed ID: 12908355
    [No Abstract]   [Full Text] [Related]  

  • 9. [Health economics play more and more important role in health care prioritization. Better utilization of the meager health care resources is the goal].
    Carlsson P; Anders A; Eliasson M
    Lakartidningen; 2006 Nov 15-21; 103(46):3617-20, 3622-3. PubMed ID: 17153871
    [No Abstract]   [Full Text] [Related]  

  • 10. [Compulsory priorities in health care: knowledge and ethical analysis are needed for decisions about who will be favoured and who will not].
    Ostman O; Axelsson M; Nilstun T; Westrin G
    Lakartidningen; 1990 Nov; 87(48):4100, 4103-4. PubMed ID: 2263126
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The National Board of Health and Welfare has the last word].
    Lindberg A; Möllergren M; Tegnell A
    Lakartidningen; 2008 May 28-Jun 3; 105(22):1685-7. PubMed ID: 18590012
    [No Abstract]   [Full Text] [Related]  

  • 13. [Reducing unnecessary laboratory use through education and regulation].
    Ohkubo A
    Rinsho Byori; 1995 Jul; 43(7):647-52. PubMed ID: 7674535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Decisions by the state, county council's money and my patient. Consequences of the LFN survey of antihypertensive agents].
    André M; Andersén-Karlsson E; Landahl S; Löfmark R; Silfverhielm B; Skoglund I
    Lakartidningen; 2008 May 21-27; 105(21):1549-50. PubMed ID: 18574990
    [No Abstract]   [Full Text] [Related]  

  • 15. [Increasing inequality in health care by separating medical indication from financial responsibility].
    Bonneux L
    Ned Tijdschr Geneeskd; 2000 Aug; 144(35):1660-2. PubMed ID: 10981230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making?
    Anell A; Persson U
    Eur J Health Econ; 2005 Sep; 6(3):274-9. PubMed ID: 15968561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Health economics evaluations are of great significance for Pharmaceutical Benefit Board's decisions].
    Persson U; Ramsberg J
    Lakartidningen; 2007 Oct 17-23; 104(42):3046-50. PubMed ID: 17985712
    [No Abstract]   [Full Text] [Related]  

  • 19. [2008 National Cardiology Guidelines: Prioritization requires consideration to other factors than scientific studies alone].
    Eklund K; Grip L; Israelsson B; Levin LA; Lindahl B; Wallentin L
    Lakartidningen; 2008 May 7-13; 105(19):1408-9; discussion 1409. PubMed ID: 18574983
    [No Abstract]   [Full Text] [Related]  

  • 20. Health and budget reform as handmaidens.
    Steuerle CE; Bovbjerg RR
    Health Aff (Millwood); 2008; 27(3):633-44. PubMed ID: 18474950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.